Endoscopic Remission

Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations and surgeries through 52 weeks of maintenance in patients with moderately to severely active disease, research showed.

Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.

SAN DIEGO — Among ulcerative colitis patients in endoscopic remission, histologic inflammation increased the risk for loss of remission, according to a presentation at Digestive Disease Week 2022.

Maintenance therapy with Skyrizi boosted clinical and endoscopic outcomes in patients with Crohn’s disease, according to a presentation at the Congress of European Crohn’s and Colitis Organization.

Among patients with Crohn’s disease, achieving a sustained clinical remission off steroids with complete endoscopic remission did not correlate with less disease progression, according to study results.

LAS VEGAS – In this video exclusive, Miguel Regueiro, MD, discussed a study assessing the risk of severe disease in postoperative patients with Crohn’s disease with isolated anastomotic disease.

Model-informed dosing of Entyvio provided data to maximize endoscopic remission rates among patients with Crohn’s disease, according to research published in Inflammatory Bowel Diseases.

Achieving endoscopic remission may be difficult for patients with Crohn’s disease with larger and deep ulcers in the ileum or rectum, according to results published in the American Journal of Gastroenterology.